International Isotopes Rebrands as Radnostix, Focusing on Radioisotopes and Theranostics
- International Isotopes Inc. has rebranded as Radnostix, Inc., reflecting its focus on radioisotopes and theranostics.
- Radnostix continues to manufacture essential radioisotope products while expanding its offerings in the theranostics market.
- Shareholders retain their stock under the ticker "INIS," with no action needed due to the name change.
Radnostix, Inc.: A New Era in Radioisotope and Theranostics Offerings
International Isotopes Inc. has officially rebranded itself as Radnostix, Inc., marking a significant transformation in the company's focus and identity. This change, initiated through a Certificate of Amendment filed in Texas, reflects Radnostix's ambition to expand beyond its traditional role as a manufacturer of industrial radioisotope products. CEO Shahe Bagerdjian articulates that the new name embodies the company's mission to establish itself as a leading partner in the burgeoning fields of radioisotopes and theranostics. This strategic pivot highlights the growing demand for innovative solutions in healthcare, particularly in the areas of diagnostics and targeted therapies.
The rebranding comes at a time when the theranostics market—integrating therapeutics and diagnostics—is experiencing rapid growth. Radnostix aims to play a pivotal role in this sector by offering a broader range of products and services that cater to the needs of healthcare providers and patients alike. The company continues to manufacture essential radioisotope products, including generic sodium iodide I-131, which is vital for treating hyperthyroidism and thyroid cancer. Additionally, Radnostix remains committed to providing contract manufacturing and supplying radioisotope active pharmaceutical ingredients (APIs) for third-party clients, further solidifying its position in the theranostics market.
While the rebranding signifies a new chapter for the company, Radnostix maintains its core operations, management team, and strategic direction. The INIS branding will still be utilized for segments focused on high energy sources, bulk radioisotopes, and stable isotopes, ensuring continuity in product offerings. The company's headquarters in Idaho Falls, Idaho, continues to serve as the hub for its manufacturing and innovation efforts. Radnostix's diverse portfolio also includes calibration and reference standards for nuclear pharmacies and imaging systems, reinforcing its commitment to quality and customer service in the radioisotope industry.
In addition to the rebranding, shareholders are informed that their common stock will continue to be traded under the ticker symbol "INIS" on the OTCQB marketplace, with future updates regarding any potential changes to the ticker symbol. Importantly, no action is required from shareholders regarding stock certificates due to the name change. For more information, the company invites stakeholders to visit its new website at radnostix.com.
The rebranding to Radnostix represents not just a change in name, but also a strategic evolution in the company's mission and offerings. As Radnostix positions itself to be at the forefront of the radioisotope and theranostics landscape, it underscores the importance of innovation and adaptability in a rapidly changing healthcare environment.